Skip to content
Screener

Gilead Sciences GILD EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Incyte logo
IncyteINCY
$2.81+37.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Precigen logo
PrecigenPGEN
-$0.02+88.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$0.11+66.7%
Celcuity logo
CelcuityCELC
-$0.97-12.8%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$183.62B+29.9%
Enterprise value$206.69B+28.3%
P/S+1.1×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions, except per share amounts)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other (income) expense, net(387)(208)(621)120
(Loss) income before income taxes(10,254)2,429(7,674)4,077
Income tax expense242468801802
Net (loss) income$(10,496)$1,960$(8,475)$3,275
Basic (loss) earnings per share$(8.45)$1.57$(6.82)$2.63
Diluted (loss) earnings per share$(8.45)$1.56$(6.82)$2.61
Shares used in basic (loss) earnings per share calculation1,2431,2451,2431,246
Shares used in diluted (loss) earnings per share calculation1,2431,2551,2431,257

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's EPS (diluted)?
Gilead Sciences (GILD) reported EPS (diluted) of -$8.45 in Q2 2026.
How has Gilead Sciences's EPS (diluted) changed year-over-year?
Gilead Sciences's EPS (diluted) decreased by 641.7% year-over-year, from $1.56 to -$8.45.
What is the long-term trend for Gilead Sciences's EPS (diluted)?
Over 4 years (2021 to 2025), Gilead Sciences's EPS (diluted) has grown at a 8.3% compound annual growth rate (CAGR), from $4.93 to $6.77.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Gilead Sciences's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude